BAP1 and hepatocellular carcinoma: Since iron-rich tumors such as HCC might be particularly responsive to agents that promote ferroptosis, BAP1 may be characterized as biomarkers of response to ferroptosis-promoting therapy, although their clinical significance remains unknown 30.